A study published in Cell Biomaterials reveals the potential of the cowpea mosaic virus (CPMV) as a low-cost cancer immunotherapy. Researchers from the University of California San Diego explored how CPMV activates the immune system to target cancer cells, distinguishing it from other plant viruses. In preclinical trials involving mouse models and canine cancer patients, CPMV demonstrated significant anti-tumor effects when injected directly into tumors. The therapy recruits various innate immune cells, including neutrophils, macrophages, and natural killer cells, to the tumor site, while also stimulating B cells and T cells to create a lasting immune memory against cancer.
Nicole Steinmetz, the study's corresponding author, expressed interest in the unique properties of CPMV that enable its anti-tumor response. The research team, led by Ph.D. student Anthony Omole, conducted a comparative analysis of CPMV and the cowpea chlorotic mottle virus (CCMV), which lacks anti-tumor effects despite similar uptake by immune cells. They found that CPMV stimulates the production of type I, II, and III interferons, known for their anti-cancer properties, while CCMV triggers a different immune response that does not effectively clear tumors.
Additionally, CPMV can be produced through molecular farming, making it a cost-effective therapy compared to many existing options that require complex manufacturing processes. The research team is now focused on advancing CPMV toward clinical trials, aiming to ensure its efficacy and safety for human patients. The study received funding from various organizations, including the National Institutes of Health and the American Cancer Society, highlighting the collaborative effort to explore this promising therapeutic avenue.